Clinical trials: Metformin, completed
Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients
The primary objective of this study is to determine if metformin administered in combination with chemotherapy to women with advanced ovarian, primary peritoneal or fallopian tube cancer will improve recurrence-free survival at…
- Trial name
- NCT01579812
- Testing
- Metformin
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Michigan Rogel Cancer Center
Diabetes Mellitus Type 2
A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.
This 3-arm study will assess the efficacy, safety and tolerability of taspoglutide compared to insulin glargine in patients with insulin-naive type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea…
- Trial name
- NCT00755287
- Testing
- insulin glargine, metformin, taspoglutide
- Where
- 210 sites in United States, Australia and 25 more
- Volunteers
- 1,072 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin
This is a Phase 3, multicenter, open-label, comparator-controlled trial comparing the effect of exenatide twice daily to twice daily biphasic insulin aspart on glycemic control, as measured by hemoglobin A1c (HbA1c).
- Trial name
- NCT00082407
- Testing
- exenatide, biphasic insulin aspart
- Where
- 69 sites in Croatia, Germany and 10 more
- Volunteers
- 505 people
- Sponsor
- AstraZeneca
Overweight, Autism Spectrum Disorder
Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
The purpose of this study is to determine whether metformin is safe and effective in the treatment of weight or weight gain in young people with Autism Spectrum Disorders (ASD) who are currently taking atypical antipsychotic…
- Trial name
- MET (NCT01825798)
- Testing
- Metformin
- Where
- 4 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Holland Bloorview Kids Rehabilitation Hospital
Breast Cancer
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer
This study is looking at whether Metformin, an agent that is commonly used to treat diabetes, can decrease or affect the ability of breast cancer cells to grow and whether Metformin will work with other therapies to keep cancer…
- Trial name
- NCT01101438
- Testing
- metformin hydrochloride
- Where
- 344 sites in United States, Canada and 2 more
- Volunteers
- 3,649 people
- Sponsor
- Canadian Cancer Trials Group
Stage 0 Breast Carcinoma, Breast Neoplasms
Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer
The purpose of this study is to determine whether it is feasible to give a combination of Metformin and omega-3 fatty acids for one year to women with a history of early stage breast cancer.
- Conditions
- Stage 0 Breast Carcinoma, Breast Neoplasms, Stage I Breast Carcinoma, Stage II Breast Carcinoma
- Trial name
- NCT02278965
- Testing
- Metformin, Omega-3 fatty acids
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Katherine D. Crew
Type 2 Diabetes Mellitus
Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes
This Phase 3, open-label, multicenter study is designed to compare the effects of exenatide and insulin glargine (Lantus® injection) on beta-cell function in patients with type 2 diabetes mellitus using metformin.
- Trial name
- NCT00097500
- Testing
- exenatide, Insulin glargine, Metformin
- Where
- 3 sites in Finland, Netherlands and 1 more
- Volunteers
- 69 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea
The primary objective of this study is to monitor the safety profile of Trajenta Duo in Korean patients with type 2 diabetes mellitus (T2DM) in a routine clinical setting.
- Trial name
- NCT01903356
- Testing
- Trajenta duo
- Where
- South Korea
- Volunteers
- 724 people
- Sponsor
- Boehringer Ingelheim
Hypogonadism, Obesity
Testosterone, Metformin, or Both, for Hypogonadism in Obese Males
The purpose of this study is to examine the effects of metformin, testosterone, or both, in males with obesity-related hypogonadism.
- Trial name
- NCT02514629
- Testing
- Metformin, Testosterone Undecanoate, Metformin + Testosterone Undecanoate
- Where
- Spain
- Volunteers
- 107 people
- Sponsor
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Diabetes Mellitus, Type 2
Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes
The objective of the study is to investigate the efficacy and safety of linagliptin 2.5 mg twice daily compared to 5 mg once daily compared to placebo given orally for 12 weeks as add-on therapy to metformin in patients with type…
- Trial name
- NCT01012037
- Testing
- linagliptin low dose, linagliptin medium dose
- Where
- 84 sites in Belgium, Canada and 7 more
- Volunteers
- 491 people
- Sponsor
- Boehringer Ingelheim
Hyperinsulinemia, Obesity
Metformin to Treat Obesity in Children With Insulin Resistance
This study will examine the safety and effectiveness of the medicine metformin to help overweight children control their food intake, weight, insulin, cholesterol, and triglyceride (blood fat) levels.
- Trial name
- NCT00005669
- Testing
- Metformin HCL
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Jack Yanovski, M.D.
PCOS
Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome
Metformin is the first-line therapy for PCOS with high metabolic risk, yet a large proportion of patients cannot tolerate it due to associated gastrointestinal adverse events.
- Trial name
- NCT03122041
- Testing
- Sitagliptin, Lifestyle intervention
- Volunteers
- 30 people
- Sponsor
- University Medical Centre Ljubljana
Healthy Volunteers
A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.
The objective of this study is to assess the effect of repeated doses of ABBV-722 on the single dose pharmacokinetics (PK) of Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin
- Trial name
- NCT07567781
- Testing
- ABBV-722, Midazolam, Metformin
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AbbVie
Diabetes Mellitus, Type 2
Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
The purpose of this clinical research study is to learn whether saxagliptin (BMS-477118) is more effective than placebo as a treatment for type 2 diabetic subjects who are not sufficiently controlled with diet and exercise
- Trial name
- NCT00121641
- Testing
- Saxagliptin, Metformin
- Where
- 134 sites in United States, Australia and 4 more
- Volunteers
- 1,035 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) and insulin degludec (IDeg) in subjects with…
- Trial name
- DUAL™ II (NCT01392573)
- Testing
- insulin degludec/liraglutide, insulin degludec
- Where
- 86 sites in United States, Bulgaria and 5 more
- Volunteers
- 413 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Non-Insulin-Dependent
Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)
After 24 weeks of treatment, to assess the A1C-lowering efficacy of sitagliptin 100 mg once daily added to the regimen of patients with inadequate glycemic control on metformin monotherapy
- Trial name
- NCT00875394
- Testing
- sitagliptin phosphate, Comparator: metformin, Comparator: Antidiabetic Standard of Care
- Volunteers
- 68 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus
Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.
The purpose of this study is to determine the efficacy of pioglitazone, twice daily (BID), combined with metformin versus pioglitazone taken alone and metformin taken alone in treating Type 2 Diabetes Mellitus.
- Trial name
- NCT00727857
- Testing
- Pioglitazone and metformin, Pioglitazone, Metformin
- Where
- 77 sites in United States, Chile and 2 more
- Volunteers
- 600 people
- Sponsor
- Takeda
Healthy
Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects
The purpose of this study is to investigate the safety and tolerability of trospium chloride (Sanctura XR™) and metformin hydrochloride (Glucophage) when co-administered.
- Trial name
- NCT00986401
- Testing
- Trospium Chloride (Sanctura XR®), Metformin hydrochloride (Glucophage®)
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Allergan
Diabetes Mellitus, Type 2
A Study To Evaluate The Safety,Tolerability, PK and PD Of DA-1241 In Healthy Male Subjects
This is a randomized, double blind, placebo controlled, single ascending dose study to assess the safety, tolerability, PK, PD and IE with metformin following a single oral dose of DA-1241 in healthy male subjects.
- Trial name
- NCT03061981
- Testing
- Metformin, DA-1241
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Diabetes Mellitus, Type 2
RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes
This study is a phase 3b, multicentre, randomised, open label, parallel group study. A 4-week run-in period will be followed by a median of 6 years of treatment with study medication in addition to continuation of background…
- Trial name
- RECORD (NCT00379769)
- Testing
- Rosiglitazone, Sulfonylurea, Metformin
- Where
- 446 sites in Australia, Belgium and 23 more
- Volunteers
- 4,447 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.